21/04/2026 Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC (Ref) Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for first-line treatment of advanced clear cell RCC. Both experimental combination re

04/08/2025 Alphamab's IND application for JSKN022 was accepted by China's CDE (Ref) Alphamab Oncology's IND application for JSKN022 (PD-L1 x integrin αvβ6 bispecific antibody-drug conjugate) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The company plans to initiate a first-in-human trial of JSKN022 for the treatment of advanced malignant solid tumors The Ph1 trial will evaluate the safety, tolerability, PK/P

30/07/2025 Phase 3 COSTAR Lung trial of dostarlimab + docetaxel ± cobolimab failed to meet the OS endpoint in previously treated NSCLC (Ref) GSK's Phase 3 COSTAR Lung/NCT04655976 trial of dostarlimab (anti-PD-1) + docetaxel ± cobolimab (anti-TIM-3) combinations did not meet the primary endpoint of improving OS vs docetaxel alone in advanced NSCLC that has progressed on prior PD-(L)1 therapy and chemotherapy. All regimens were well tolerated and toxicities were consistent with